{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:14:40Z","timestamp":1793146480741,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xcrm.2025.102515","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:36:37Z","timestamp":1765899397000},"page":"102515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-8429","authenticated-orcid":false,"given":"Ce","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingye","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiguang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingpei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongzhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongting","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102515_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102515_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102515_bib4","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2025.102515_bib5","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220745","article-title":"An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery","volume":"219","author":"Shen","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102515_bib6","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1038\/s41467-024-49034-1","article-title":"Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses","volume":"15","author":"Zou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102515_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2025.102515_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trecan.2023.11.008","article-title":"Harnessing CD8 T cell responses using PD-1\u2013IL-2 combination therapy","volume":"10","author":"Hashimoto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2025.102515_bib9","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.200363097","article-title":"IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102515_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102515_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102515_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-800267-4.00005-5","article-title":"Interleukin 10 Receptor Signaling","volume":"14","author":"Shouval","year":"2014","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the Interleukin-10 Receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101325","article-title":"Immune regulation and cytotoxic T cell activation of IL-10 agonists \u2013 Preclinical and clinical experience","volume":"44","author":"Oft","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 Elicits IFN\u03b3-Dependent Tumor Immune Surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102515_bib18","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2025.02.002","article-title":"Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization","volume":"188","author":"Chang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102515_bib20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","article-title":"Interleukin-10 in cancer immunotherapy: from bench to bedside","volume":"9","author":"Salkeni","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2025.102515_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102515_bib22","first-page":"3562","article-title":"Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.xcrm.2025.102515_bib23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","article-title":"Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial","volume":"20","author":"Naing","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102515_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","article-title":"Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)","volume":"16","author":"Spigel","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2025.102515_bib25","first-page":"1108","article-title":"Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.xcrm.2025.102515_bib26","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102515_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102515_bib28","doi-asserted-by":"crossref","first-page":"13552","DOI":"10.1074\/jbc.275.18.13552","article-title":"Design and Analysis of an Engineered Human Interleukin-10 Monomer","volume":"275","author":"Josephson","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102515_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc0653","article-title":"Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses","volume":"13","author":"Gorby","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2025.102515_bib30","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102515_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8433","article-title":"Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10","volume":"371","author":"Saxton","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102515_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2001.1504","article-title":"Preclinical Safety Evaluation of Recombinant Human Interleukin-10","volume":"35","author":"Rosenblum","year":"2002","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102515_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.xcrm.2025.102515_bib34","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro","volume":"182","author":"Leidi","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102515_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jlb.58.3.351","article-title":"IL-10 up-regulates human monocyte phagocytosis in the presence of IL-4 and IFN-\u03b3","volume":"58","author":"Capsoni","year":"1995","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.xcrm.2025.102515_bib36","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.4049\/jimmunol.149.12.4048","article-title":"IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10","volume":"149","author":"te Velde","year":"1992","journal-title":"J. Immunol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:47:29Z","timestamp":1774936049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666379125005889"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102515","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Guangdong Fapon Biopharma Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102515"}}